Literature DB >> 1312985

Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis.

S Fargion1, C Mandelli, A Piperno, B Cesana, A L Fracanzani, M Fraquelli, P A Bianchi, G Fiorelli, D Conte.   

Abstract

Two hundred twelve Italian patients with genetic hemochromatosis (181 men, mean age 50 +/- 11 yr; and 31 women, mean age 49 +/- 10 yr) were followed for a median period of 44 mo (range = 3 to 218 mo). Alcohol abuse was present in 31 subjects (15%), and chronic HBV and HCV infection were seen in 19 (9%) and 35 (24%) of 145 cases tested, respectively. Twenty-four patients (11%) had concomitant beta-thalassemia trait. Liver biopsy revealed cirrhosis in 146 and a noncirrhotic pattern in the other 66. Perls' stain was degree III in 37 patients and IV in 171 patients. One hundred eighty-five patients underwent weekly venesection, and iron depletion was achieved in 122 cases after total iron removal of 3 to 41 gm. Death occurred in 44 patients after 3 to 198 mo and was due to hepatocellular carcinoma in 20 cases, liver failure in 10, extrahepatic cancer in six, heart failure in three and hemochromatosis unrelated causes in five. Cancer has developed in seven other patients still alive (hepatocellular in five and extrahepatic in two). No deaths were observed among noncirrhotic patients; cumulative survival rates in cirrhotic patients were 85%, 75%, 60% and 47% at 3, 5, 8 and 10 yr, respectively. Univariate analysis in the 146 cirrhotic patients showed that age greater than 60 yr, alcohol abuse, cardiomyopathy, skin pigmentation, portal hypertension, hypoalbuminemia, hypergammaglobulinemia and Child class B or C had significant negative prognostic value. At multivariate analysis, only alcohol abuse, gamma-globulins greater than 2.0 gm/dl and Child class B or C maintained their negative prognostic values (p less than 0.01, hazard ratio 2.7; p less than 0.001, hazard ratio 2.8; and p less than 0.001, hazard ratio 4.3, respectively).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312985     DOI: 10.1002/hep.1840150417

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

Review 1.  Hepatocellular carcinoma: updates in primary prevention.

Authors:  Will J Fecht; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2004-02

2.  Elevated serum transferrin saturation and mortality.

Authors:  Arch G Mainous; James M Gill; Peter J Carek
Journal:  Ann Fam Med       Date:  2004 Mar-Apr       Impact factor: 5.166

Review 3.  Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies?

Authors:  Eng K Gan; Oyekoya T Ayonrinde; Debbie Trinder; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 4.  Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice.

Authors:  Kristina M Utzschneider; Kris V Kowdley
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

5.  Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis.

Authors:  Paola Dongiovanni; Anna Ludovica Fracanzani; Gaetano Cairo; Chiara Paola Megazzini; Stefano Gatti; Raffaela Rametta; Silvia Fargion; Luca Valenti
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

6.  HFE mutations in heart disease.

Authors:  Terence Dunn; Derek Blankenship; Nicole Beal; Richard Allen; Eliot Schechter; William Moore; Ghazala Perveen; June Eichner
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

7.  The significance of haemochromatosis gene mutations in the general population: implications for screening.

Authors:  M J Burt; P M George; J D Upton; J A Collett; C M Frampton; T M Chapman; T A Walmsley; B A Chapman
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 8.  Hepatic iron overload and hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

9.  Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis.

Authors:  V Boige; L Castéra; N de Roux; N Ganne-Carrié; B Ducot; G Pelletier; M Beaugrand; C Buffet
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

10.  Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis.

Authors:  Fei Jin; Li-Shuai Qu; Xi-Zhong Shen
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.